Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]

IF 3.5 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2025-10-01 DOI:10.1016/j.jtocrr.2025.100892

Marina C. Garassino MD , Shirish Gadgeel MD , Silvia Novello MD, PhD , Balazs Halmos MD , Enriqueta Felip MD , Giovanna Speranza MD , Rina Hui PhD , Edward B. Garon MD , Hidehito Horinouchi MD, PhD , Shunichi Sugawara MD, PhD , Delvys Rodriguez-Abreu MD, PhD , Martin Reck MD , Razvan Cristescu PhD , Deepti Aurora-Garg PhD , Andrey Loboda PhD , Jared Lunceford PhD , Julie Kobie PhD , Mark Ayers MS , Bilal Piperdi MD , M. Catherine Pietanza MD , Luis Paz-Ares MD, PhD